Medicinova Stock Today
| MNOV Stock | USD 1.55 0.08 5.44% |
PerformanceVery Weak
| Odds Of DistressLow
|
MediciNova is selling for under 1.55 as of the 17th of March 2025; that is 5.44 percent increase since the beginning of the trading day. The stock's lowest day price was 1.46. MediciNova has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of February 2005 | Category Healthcare | Classification Health Care |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. The company has 49.05 M outstanding shares of which 300.71 K shares are now shorted by private and institutional investors with about 13.14 trading days to cover. More on MediciNova
Moving together with MediciNova Stock
| 0.66 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.68 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
| 0.74 | EVO | Evotec SE ADR | PairCorr |
Moving against MediciNova Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MediciNova Stock Highlights
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMediciNova can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MediciNova's financial leverage. It provides some insight into what part of MediciNova's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MediciNova (MNOV) is traded on NASDAQ Exchange in USA. It is located in 4275 Executive Square, La Jolla, CA, United States, 92037 and employs 13 people. MediciNova is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.02 M. MediciNova conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.05 M outstanding shares of which 300.71 K shares are now shorted by private and institutional investors with about 13.14 trading days to cover.
MediciNova currently holds about 65.23 M in cash with (10.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.33.
Check MediciNova Probability Of Bankruptcy
Ownership AllocationMediciNova maintains a total of 49.05 Million outstanding shares. Roughly 75.07 % of MediciNova outstanding shares are held by general public with 2.98 pct. owned by insiders and only 21.95 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MediciNova Ownership Details
MediciNova Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 122 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 96.2 K | |
| Barclays Plc | 2024-12-31 | 95.6 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 71.5 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 66.2 K | |
| Sbi Securities Co Ltd | 2024-12-31 | 53.8 K | |
| Y-intercept (hong Kong) Ltd | 2024-12-31 | 37 K | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 35.8 K | |
| Millennium Management Llc | 2024-12-31 | 25.9 K | |
| Essex Woodlands Health Ventures | 2024-12-31 | 1.1 M | |
| Blackrock Inc | 2024-12-31 | 701.8 K |
MediciNova Historical Income Statement
MediciNova Stock Against Markets
MediciNova Corporate Management
| Jason CPA | CFO Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Yuichi MD | President, CoFounder | Profile | |
| MD MPH | Chief Director | Profile | |
| John CPA | Controller | Profile |
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.